Le Centre de référence sur les agents tératogènes (CRAT) : une structure pionnière

Eléfant, Élisabeth; Vauzelle, C.; Beghin, Delphine

doi:10.2515/therapie/2014004

Cited by 11 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review was based on the available guidelines, articles or information from the French pharmacovigilance centers and national agencies (French National Agency for Medicines and Health Products Safety, Centre de Réference sur les Agents Tératogènes or CRAT). The CRAT is the first national and international public organization especially involved in the problem of drugs during pregnancy [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)

et al. 2018

View full text Add to dashboard Cite

BackgroundShared decision-making (SDM) is a model of interaction between doctors and patients in which both actors contribute to the medical decision-making process. SDM has raised great interest in mental healthcare over the last decade, as it is considered a fundamental part of patient-centered care. However, there is no research evaluating the efficacy of SDM compared to usual care (CAU), as it relates to quality of care and more specifically treatment adherence, in bipolar disorder (BD).Methods/DesignThis is a 12-month multi-centre, cluster-randomized controlled trial comparing the efficacy of SDM to CAU. Adult BD patients (n = 300) will be eligible after stabilization for at least 4 weeks following an acute mood episode. The intervention will consist of applying the standardized SDM process as developed by the Ottawa Hospital Research Institute in order to choose the maintenance treatment of BD. A multidisciplinary team developed a decision aid “choose my long-term treatment with my doctor” for BD patients to clarify possible therapeutic options. Primary outcome will assess the patient’s level of adherence (based on hetero-evaluation) of ongoing treatment at 12 months. Secondary outcomes will assess the difference between the 2 groups of patients in terms of adherence to maintenance drug therapy based on other measures (self-assessment scale and plasma levels of mood stabilizers). Additionally, other dimensions will be assessed: decisional conflict, satisfaction with care and involvement in decision making, beliefs about treatment, therapeutic relationship, knowledge about information for medical decision and clinical outcomes (depression, mania, functioning and quality of life).The primary endpoint will be analysed without adjustment by comparison of adherence scores between the two groups using Student t-tests or Mann–Whitney tests according to the variable distribution. A set of secondary analyses will be adjusted for covariates of clinical interest using generalized linear mixed regression models.DiscussionThis will be the first study evaluating the effect of an SDM intervention on patient adherence in BD. This is also an innovative protocol because it proposes the development of an evidence-based tool that should help patients and clinicians to initiate discussions regarding the use of BD treatment.Trial registrationThe study has been registered with ClinicalTrials.gov as NCT03245593.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Briefly, several antifungals belonging to azol family (Clotrimazole and Sertaconazole) are used for all terms of pregnancy, while others antifungals are avoided during the first trimester such as Econazole and Tioconazole. However, regarding the risk of treatment failure with the above drugs, the use of oral Fluconazole treatment (Beagyne) in a single dose of 150 mg, within all pregnancy terms is well recommended [14]. In addition, AmB is considered as the treatment of choice for invasive candidiasis in pregnant women [15].…”

Section: Introductionmentioning

confidence: 99%

“…Though not widely followed, several countries, such as Germany, recommend a systematic prophylactic treatment for asymptomatic Candida colonization in pregnant women in the third trimester of pregnancy [13]. In Tunisia, VVC treatment during pregnancy considers updated international guidelines protocols such as CRAT ‘Centre de Référence sur les Agents Tératogènes’ [14]. Briefly, several antifungals belonging to azol family (Clotrimazole and Sertaconazole) are used for all terms of pregnancy, while others antifungals are avoided during the first trimester such as Econazole and Tioconazole.…”

Section: Introductionmentioning

confidence: 99%

Microbiological and molecular screening of Candida spp. isolated from genital tract of asymptomatic pregnant women

Bouglita

Rabhi

Raich

et al. 2022

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Candida spp. may cause opportunistic infections called vulvovaginal candidiasis (VVC), which is estimated to be the second most common cause of vaginitis worldwide. Gap Statement. Under various circumstances, VVC could compromise pregnancy outcomes. Emerging data suggests that VVC during pregnancy may be associated with increased risk of complications and congenital cutaneous candidiasis. Aim. To assess the prevalence of Candida spp. in asymptomatic pregnant women and determine the susceptibility of the isolates to antifungal drugs. Methodology. In a prospective cohort, 65 high vaginal swab samples of consented pregnant women. Candida isolates were identified using both microbiological and molecular tools and drug susceptibilities were profiled. Results. The prevalence of VVC among our study participants was 37 %, 24 of the 65 asymptomatic pregnant women show Candida spp. colonization. C. albicans was the most common species 61 %, followed by C. glabrata 39 %. In addition, a significant fraction of the isolated colonies showed resistance to Fluconazole, with a ratio of 63 % for C. albicans isolates and 16 % for Candida glabrata isolates. Moreover, relative quantification of genes related to resistance to fluconazole, CDR1, ERG11 as well as HWP1, showed a significant change compared to controls. Conclusion. Monitoring of vaginal Candida colonization before the third trimester of pregnancy, that could reduce congenital Candida colonization and risk of pregnancy complications.

show abstract

French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancy

Belzeaux,

Gressier,

Boudieu

et al. 2024

Arch Womens Ment Health

View full text Add to dashboard Cite

Le Centre de référence sur les agents tératogènes (CRAT) : une structure pionnière

Cited by 11 publications

References 1 publication

Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)

Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)

Microbiological and molecular screening of Candida spp. isolated from genital tract of asymptomatic pregnant women

French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancy

Contact Info

Product

Resources

About